FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy Volunteers
In brief
The study will comprise primarily a single-ascending dose (SAD) escalation component.
Key facts
- Study ID
- NCT03970122
- Run by
- Goldfinch Bio, Inc.
- People needed
- 70
- Starts
- 2019-05-29
- Expected to finish
- 2020-04-04
- Last updated by the study team
- 2020-06-02
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Covance Clinical Research Unit Inc. — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.